LPCN
BEARISH
$2.38
Live
Lipocine Inc. · NASDAQ
Target $11.0
(+362.2%)
$1.81
52W Range
$12.37
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 14, 2026
Market cap
$17.37M
P/E
N/A
ROE
-54.3%
Profit margin
N/A
Debt/Equity
0.03
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
95%
LPCN exhibits critical fundamental weakness, highlighted by a Piotroski F-Score of 0/9, indicating severe deterioration across all financial health dimensions. While the company maintains a strong liquidity position with a current ratio of 6.68 and negligible debt, these are offset by a catastrophic 67.2% year-over-year revenue collapse and an operating margin of -219.65%. The technical trend is entirely bearish (0/100), and the stock has lost over 90% of its value over five years. Despite a lone analyst's optimistic $11.00 target, the data suggests a company in operational distress.
Key Strengths
Very low debt-to-equity ratio (0.03)
Strong short-term liquidity (Current Ratio 6.68)
Trading near book value (P/B 1.01)
High gross margin (100%)
Positive surprise in most recent quarterly EPS estimate
Key Risks
Severe revenue decline (-67.2% YoY)
Critical financial health score (Piotroski 0/9)
Extreme negative operating margins (-219.65%)
Micro-cap volatility and low market capitalization ($0.02B)
Consistent long-term price depreciation (5Y Change -90.5%)
AI Fair Value Estimate
Based on comprehensive analysis
$2.1
-11.8% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
13
Weak
30
10
5
20
0
AI Verdict
High Risk / Speculative
Key drivers: Piotroski F-Score 0/9, Revenue collapse, Bearish technicals, Strong liquidity runway
Confidence
90%
Value
30/100
Ref P/E N/A, P/S 8.79, P/B 1.01
Positives
- P/B ratio of 1.01 suggests it is not trading at a significant premium to assets
Watchpoints
- P/S ratio of 8.79 is excessive given the revenue decline
- No Graham Number available due to lack of earnings
Future
10/100
Ref Growth rates
Positives
- Recent Q/Q EPS growth improvement
Watchpoints
- YoY Revenue growth of -67.20%
- Negative forward P/E
Past
5/100
Ref Historical trends
Positives
- Occasional earnings beats
Watchpoints
- 5-year price change of -90.5%
- Consistent failure to maintain revenue levels
Health
20/100
Ref Piotroski F-Score
Positives
- Low Debt/Equity
- High Quick Ratio (6.36)
Watchpoints
- Piotroski F-Score 0/9 indicates total fundamental failure
Dividend
0/100
Ref Yield N/A
Positives
No standout positives identified.
Watchpoints
- No dividend history
- No payout capacity
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$2.38
Analyst Target
$11.0
Upside/Downside
+362.2%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for LPCN and closest competitors.
Updated 2026-04-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
LPCN
Lipocine Inc.
Primary
|
-90.5% | -50.9% | -23.7% | -23.5% | -67.6% | +22.7% |
|
CUE
Cue Biopharma, Inc.
Peer
|
-98.5% | -94.2% | -69.9% | -75.0% | -37.5% | -18.2% |
|
IINN
Inspira Technologies Oxy B.H.N. Ltd.
Peer
|
-91.0% | -65.5% | -31.4% | -62.4% | -26.0% | -11.8% |
|
GNTA
Genenta Science S.p.A.
Peer
|
-93.8% | -88.7% | -82.4% | -79.4% | -21.2% | -4.4% |
|
HBIO
Harvard Bioscience, Inc.
Peer
|
-93.5% | -91.5% | +10.5% | +2.6% | -15.5% | -17.1% |
LPC
Lipocine Inc.
Primary
5Y
-90.5%
3Y
-50.9%
1Y
-23.7%
6M
-23.5%
1M
-67.6%
1W
+22.7%
CUE
Cue Biopharma, Inc.
Peer
5Y
-98.5%
3Y
-94.2%
1Y
-69.9%
6M
-75.0%
1M
-37.5%
1W
-18.2%
IIN
Inspira Technologies Oxy B.H.N. Ltd.
Peer
5Y
-91.0%
3Y
-65.5%
1Y
-31.4%
6M
-62.4%
1M
-26.0%
1W
-11.8%
GNT
Genenta Science S.p.A.
Peer
5Y
-93.8%
3Y
-88.7%
1Y
-82.4%
6M
-79.4%
1M
-21.2%
1W
-4.4%
HBI
Harvard Bioscience, Inc.
Peer
5Y
-93.5%
3Y
-91.5%
1Y
+10.5%
6M
+2.6%
1M
-15.5%
1W
-17.1%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-1.92
PEG Ratio
N/A
P/B Ratio
1.01
P/S Ratio
8.79
EV/Revenue
1.5
EV/EBITDA
-0.29
Market Cap
$17.37M
Profitability
Profit margins and return metrics
Profit Margin
N/A
Operating Margin
-219.65%
Gross Margin
100.0%
ROE
-54.28%
ROA
-32.81%
Growth
Revenue and earnings growth rates
Revenue Growth
-67.2%
Earnings Growth
N/A
Q/Q Revenue Growth
-67.19%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.03
Low debt
Current Ratio
6.68
Strong
Quick Ratio
6.36
Excellent
Cash/Share
$2.04
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Op. Margin
-219.6%
Net Margin
-206.9%
Total Assets
$0.0B
Liabilities
$0.0B
Equity
$0.0B
Debt/Equity
0.17x
Operating CF
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
100%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-03-10
$-0.42
+31.1% surprise
2025-11-06
$-0.59
-9.3% surprise
2025-08-14
$N/A
2025-08-05
$-0.41
-2.5% surprise
Healthcare Sector Comparison
Comparing LPCN against 319 companies in the Healthcare sector
(20 bullish, 107 neutral, 192 bearish)
Return on Equity (ROE)
-54.28%
This Stock
vs
-86.0%
Sector Avg
-36.9%
(Below Avg)
Debt to Equity
0.03
This Stock
vs
3.51
Sector Avg
-99.1%
(Less Debt)
Revenue Growth
-67.2%
This Stock
vs
90.15%
Sector Avg
-174.5%
(Slower)
Current Ratio
6.68
This Stock
vs
3.67
Sector Avg
+82.1%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
LPCN
Lipocine Inc.
|
BEARISH | $17.37M | - | -54.3% | -% | $2.38 | |
|
CUE
Cue Biopharma, Inc.
|
NEUTRAL | $18.38M | - | -121.1% | -96.9% | $0.19 | Compare |
|
IINN
Inspira Technologies Oxy...
|
BEARISH | $18.52M | - | -397.9% | -% | $0.42 | Compare |
|
GNTA
Genenta Science S.p.A.
|
BEARISH | $16.02M | - | -38.0% | -% | $0.68 | Compare |
|
HBIO
Harvard Bioscience, Inc.
|
BEARISH | $19.27M | - | -147.1% | -65.5% | $4.31 | Compare |
LPCN
Lipocine Inc.
BEARISH
Mkt Cap
$17M
P/E
-
ROE
-54.3%
Price
$2.38
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-07 | HIGUCHI JOHN W | Director | Purchase | 40,000 | $81,200 |
| 2026-04-06 | HIGUCHI JOHN W | Director | Purchase | 123,000 | $252,150 |
| 2026-04-06 | PATEL MAHESH V | Chief Executive Officer | Purchase | 25,000 | $50,750 |
| 2026-04-02 | PATEL MAHESH V | Chief Executive Officer | Purchase | 25,000 | $231,250 |
HIGUCHI JOHN W
Director
2026-04-07
40,000 shares
·
$81,200
HIGUCHI JOHN W
Director
2026-04-06
123,000 shares
·
$252,150
PATEL MAHESH V
Chief Executive Officer
2026-04-06
25,000 shares
·
$50,750
PATEL MAHESH V
Chief Executive Officer
2026-04-02
25,000 shares
·
$231,250
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
1 analysts
HC Wainwright & Co.
2026-04-06
Buy
Neutral
HC Wainwright & Co.
2026-01-21
Buy
Buy
HC Wainwright & Co.
2025-11-13
Buy
Buy
Past News Coverage
Recent headlines mentioning LPCN from our newsroom.
Newest → oldest
No matching news yet.